Turn Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TTRX research report →
Price Chart
About the company
Turn Therapeutics Inc. , officially known as Global Health Solutions, Inc. , is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes.
- CEO
- Bradley E. Burnam
- IPO
- 2025
- Employees
- 2
- HQ
- Westlake Village, CA, US
Get TickerSpark's AI analysis on TTRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $247.49M
- P/E
- -20.00
- PEG
- 0.25
- P/S
- 0.00
- P/B
- 45.89
- EV/EBITDA
- -59.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -297.32%
- ROIC
- -52.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-5,858,648
- Net Income
- $-3,194,080-80.6%
- EPS
- $-0.23-76.9%
- OCF Growth
- -88.3%
- FCF Growth
- -85.9%
- 52W High
- $16.45
- 52W Low
- $2.70
- 50D MA
- $11.32
- 200D MA
- $7.37
- Beta
- 2.04
- RSI (14)
- 35
- Avg Volume
- 119.32K
No earnings-call transcripts are available for TTRX yet.
- Free Float
- 36.2%
- Shares Outstanding
- 30.57M
- Float Shares
- 11.07M
of shares held by institutions
29 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 423.89K | ▲ 349.59K |
| Blackrock, Inc. | 259.03K | ▲ 220.44K |
| Ieq Capital, LLC | 227.40K | 0 |
| Geode Capital Management, LLC | 158.63K | ▲ 141.49K |
| Morgan Stanley | 139.67K | ▲ 128.33K |
| Millennium Management LLC | 60.55K | ▼ 9.21K |
| Hrt Financial LP | 57.45K | ▲ 57.45K |
| Vanguard Fiduciary Trust Co | 36.05K | ▲ 23.57K |
| Vanguard Group Inc | 30.16K | ▲ 30.16K |
| Tamar Securities, LLC | 30.00K | 0 |
| Royal Bank Of Canada | 28.25K | ▲ 28.25K |
| Bridgewater Advisors Inc. | 27.33K | ▲ 27.33K |
Held by 28 ETFs
Biggest fund positions in TTRX by dollar value.
Our TTRX coverage
Recent articles, reports, and earnings notes.
No research on TTRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TTRX report →Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London
businesswire.com · Nov 16
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
gurufocus.com · Nov 9
Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 9
Turn Therapeutics' GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program
businesswire.com · Nov 5
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
businesswire.com · Oct 21
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
gurufocus.com · Sep 9
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
businesswire.com · Sep 9
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
gurufocus.com · Aug 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.